The article reports on the efforts of major drug companies including GlaxoSmithKline, Abbott Laboratories Inc. and Vivus Inc. to develop drugs for weight loss in the U.S. GlaxoSmithKline sells Alli, a low dosage over-the-counter version of the drug Xenical that can speed up weight loss by ...
While Mounjaro had already been used by some patients "off-label" for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too. Zepbound will be available for patients in the U.S. by t...
In the past year, Eli Lilly is up 90%, while Novo Nordisk has gained 68%, as of Friday's market close. Mazza waived concerns that investors have missed out on the rally, noting the weight loss drug industry is still in its "early days." "The m...
New GLP-1 weight loss drugs may have the power to reshape industries, with mixed impacts already being reported by Walmart and Kroger.
Shares of Corbus, which is working on a similar weight-loss drug, crashed 62.3% to 19.51.Meanwhile, shares of companies working on GLP-1-based drugs jumped. Eli Lilly (LLY) stock rose 0.7% to 921.49. Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) advanced ...
MOLECULAR WEIGHT 748.3 SPONSOR Bristol-Myers Squibb CODE DESIGNATION ………..BMS-650032 CAS REGISTRY NUMBER 630420-16-5 Asunaprevir (formerly BMS-650032) is an experimental drug candidate for the treatment of hepatitis C. It is undergoing development by Bristol-Myers Squibb and is currently inPhase...
The study highlights a critical disparity in drug access. Medicare, for example, doesn’t cover these drugs for weight loss and Medicaid coverage varies widely by state. Expanding access to these medications is not just a matter of improving treatment options but also a crucial public health inte...
number and value, most likely because the most promising assets are being developed internally by large pharmaceutical companies, such as Novo Nordisk and Eli Lilly. The number and value of deals may increase as companies looking for ways to enter the weight-loss space develop next-generation ...
Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound.
but animal studies suggest it is distributed differently in the brain.) When an early Wegovy trial showed the drug’s power, Kurtzhals says it felt “too good to be true”. Then a late-stage trial confirmed the stunning weight loss, and the team celebrated. “They felt like they had won...